Changes Afoot in the Management of CKD Mineral Bone Disorder Reinforced by a Clinical Practice Guideline Update from KDIGO
According to RealTime Dynamix™: Bone and Mineral Metabolism, a quarterly report published by Spherix Global Insights, the migration to non-calcium based binders, with accelerated adoption of Keryx’s Auryxia and FMC’s Velphoro, is expected to continue Download Report Overview EXTON, Pa., Aug. 10, 2017 /PRNewswire/ — Since the introduction of Renagel by Genzyme Corporation nearly 20 […]
New Study of More Than 1,000 Dialysis Patients Reveals Significant Opportunity for Improvement of Hyperphosphatemia and Highlights the Potential for Amgen’s Parsabiv
According to a new study published by Spherix Global Insights, close to half of the dialysis patients treated with phosphate binders are above the target phosphorus level Download Report Overview EXTON, Pa., Aug. 3, 2017 /PRNewswire/ — According to the latest RealWorld Dynamix: Dialysis report, more than one-third of the dialysis patients were above target […]
RealWorld Dynamix™: Dialysus US 2017
The management of renal anemia in dialysis patients as well as in those with later stage chronic kidney disease is becoming increasingly complex. In the dialysis setting, clinical management is further complicated by a reimbursement model that treats commonly used therapies like erythropoiesis stimulating agents (ESAs) and iron therapies as cost centers. Novel products in […]
Keryx’s Auryxia and Vifor-FMC’s Velphoro Slowly Gaining Share in the Phosphate Binder Market While Big Shifts in CKD-MBD Loom With the Pending Introduction of Amgen’s Parsabiv
Over 300 US nephrologists and renal dietitians (RD) describe future practice pattern changes in most recent quarterly update by Spherix Global Insights. Download Report Overview EXTON, Pa., May 10, 2017 /PRNewswire/ — In a market long dominated by Sanofi-Genzyme’s Renvela, there are signs that the newer non-calcium, iron-based binders (Keryx’s Auryxia and Vifor-FMC’s Velphoro) are […]
RealTime Dynamix™: Hyperkalemia (Neph) US Q2
The hyperkalemia market underwent sweeping changes with the introduction of Relypsa’s Veltassa in the beginning of 2016. Veltassa represented the first new therapy for the treatment of hyperkalemia in over 50 years. In 2017, a new competitor in AstraZeneca/ZS Pharma’s ZS-9 may come into play after being delayed by a Complete Response Letter in 2016. […]
RealTime Dynamix™: Bone and Mineral US Q2
The management of hyperphosphatemia, secondary hyperparathyroidism and vitamin D deficiency are challenging conditions to manage in dialysis patients. These conditions are also highly prevalent in later-stage CKD-ND patients.Current therapeutic options have multiple limitations and are associated with poor adherence. Recent launches of iron-based, non-calcium phosphate binders have not measurably shifted the market. This monthly report […]
Relypsa’s Veltassa Dodges the Competition Bullet as FDA Hands AstraZeneca a Second Complete Response Letter for Hyperkalemia Agent, ZS-9
Delay gives Relypsa time to close the nephrology-to-cardiology gap for Veltassa Download Report Overview March 20, 2017 – Cambridge, Massachusetts. Sixteen months and $2.7 billion ago, ZS Pharma’s hyperkalemia candidate (ZS-9, sodium zirconium cyclosilicate) was one of the most highly anticipated drugs in the renal market. Since being acquired by AstraZeneca, the company last week […]
RealTime Dynamix™: Bone and Mineral US Q1
The management of hyperphosphatemia, secondary hyperparathyroidism and vitamin D deficiency are challenging conditions to manage in dialysis patients. These conditions are also highly prevalent in later-stage CKD-ND patients.Current therapeutic options have multiple limitations and are associated with poor adherence. Recent launches of iron-based, non-calcium phosphate binders have not measurably shifted the market. This monthly report […]
RealTime Dynamix™: Hyperkalemia (Neph) Q1
The hyperkalemia market underwent sweeping changes with the introduction of Relypsa’s Veltassa in the beginning of 2016. Veltassa represented the first new therapy for the treatment of hyperkalemia in over 50 years. In 2017, a new competitor in AstraZeneca/ZS Pharma’s ZS-9 may come into play after being delayed by a Complete Response Letter in 2016. […]
Keryx’s Supply Interruption Of Auryxia And The Delayed Approval For Amgen’s Parsabiv Shake Things Up In The Renal Market
Download Report Overview ZUG, Switzerland, Sept. 20, 2016— While nephrologists are stating that the recent supply interruption of Keryx’s phosphate binder, Auryxia, does not have a major impact on their practice, the challenge for Keryx will be the re-build – 48% of the nephrologists that had patients on Auryxia, anticipate a slow uptake once supply […]
